187 related articles for article (PubMed ID: 10430255)
21. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
[TBL] [Abstract][Full Text] [Related]
23. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Petrioli R; Paolelli L; Francini E; Manganelli A; Salvestrini F; Francini G
Urology; 2007 Jan; 69(1):142-6. PubMed ID: 17270637
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L
Anticancer Res; 2005; 25(6C):4475-9. PubMed ID: 16334129
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
26. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Lustberg MB; Pant S; Ruppert AS; Shen T; Wei Y; Chen L; Brenner L; Shiels D; Jensen RR; Berger M; Mrozek E; Ramaswamy B; Grever M; Au JL; Wientjes MG; Shapiro CL
Cancer Chemother Pharmacol; 2012 Jul; 70(1):49-56. PubMed ID: 22729159
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
George S; Dreicer R; Au JJ; Shen T; Rini BI; Roman S; Cooney MM; Mekhail T; Elson P; Wientjes GM; Ganapathi R; Bukowski RM
Clin Genitourin Cancer; 2008 Sep; 6(2):79-85. PubMed ID: 18824429
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
30. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
31. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
33. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Trivedi C; Redman B; Flaherty LE; Kucuk O; Du W; Heilbrun LK; Hussain M
Cancer; 2000 Jul; 89(2):431-6. PubMed ID: 10918176
[TBL] [Abstract][Full Text] [Related]
34. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Petrioli R; Pascucci A; Conca R; Chiriacò G; Francini E; Bargagli G; Fiaschi AI; Manganelli A; De Rubertis G; Barbanti G; Ponchietti R; Francini G
Br J Cancer; 2011 Feb; 104(4):613-9. PubMed ID: 21285986
[TBL] [Abstract][Full Text] [Related]
37. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Ellerhorst JA; Tu SM; Amato RJ; Finn L; Millikan RE; Pagliaro LC; Jackson A; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2371-6. PubMed ID: 9815636
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
